Disclaimer for the US market

The products and information provided on this website are intended for healthcare professionals. These products are not for sale or distribution in the United States and statements made regarding these products have not been evaluated by the U.S. Food and Drug Administration (FDA). The efficacy of these products has not been confirmed by FDA-approved research and these products are therefore not intended to diagnose, treat, cure or prevent any disease. All information presented here is for general information purposes only and not meant as a substitute for or alternative to advice from healthcare practitioners. The Federal Food, Drug and Cosmetic Act requires this notice.

Neither the Company nor its representatives is providing any medical advice, and none should be inferred, from any ideas, suggestions, testimonials or other information set forth on this website or in other Company materials or provided over the phone, in the mail, in product packaging, or in email correspondence. This website may contain links to third-party websites. The Company provides these links as a convenience only and does not endorse any of these sites. The Company is not responsible for the content of, and does not make any representations regarding the materials on, such linked third-party websites. If you decide to access or rely on information at linked third-party website, you do so at our own risk. Our terms and conditions, including disclaimers, are more fully set forth in our Terms of Use, Privacy Policy and Terms of Online Sales.

CARL. bei der Jahrestagung der DGK in Mannheim

Mit einem CARL Messestand ist die Resuscitec vom 12. bis 15. April bei der 89. Jahrestagung der Deutschen Gesellschaft für Kardiologie (DGK) in Mannheim vor Ort. Die Präsenzveranstaltung adressiert in diesem Jahr das Thema „Epidemie Herzinsuffizienz: Mechanismen erforschen, Herzen heilen!“.  In der Session „Mechanical Short-Term Support: State of the Art“, am 14. April, werden auch für CARL relevante ECPR-Versorgungskonzepte zur Behandlung von Patienten mit Herzstillstand diskutiert.

Treffen Sie uns im Congress Center Rosengarten in Mannheim am Stand Nr. 141 auf der Ebene 0 und erörtern Sie mit unserem CARL Academy-Team, wie die CARL Therapie und die CARL Technologie in Ihr interdisziplinäres ECPR-Programm implementiert werden können.

CARL. The Next Level of ECPR.

Weitere Informationen: 89. Jahrestagung (dgk.org)


< Zurück